{"id":817020,"date":"2025-02-24T16:25:42","date_gmt":"2025-02-24T21:25:42","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/zentalis-pharmaceuticals-to-participate-in-upcoming-investor-conferences\/"},"modified":"2025-02-24T16:25:42","modified_gmt":"2025-02-24T21:25:42","slug":"zentalis-pharmaceuticals-to-participate-in-upcoming-investor-conferences","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/zentalis-pharmaceuticals-to-participate-in-upcoming-investor-conferences\/","title":{"rendered":"Zentalis Pharmaceuticals to Participate in Upcoming Investor Conferences"},"content":{"rendered":"<div class=\"mw_release\">\n<p align=\"justify\">SAN DIEGO, Feb.  24, 2025  (GLOBE NEWSWIRE) &#8212; Zentalis<sup>\u00ae<\/sup> Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical-stage biopharmaceutical company developing a potentially first-in-class and best-in-class WEE1 inhibitor for patients with ovarian cancer and other tumor types, today announced that members of the management team will participate in the following upcoming investor conferences:<\/p>\n<ul>\n<li>TD Cowen 45th Annual Health Care Conference, Boston, MA. Fireside discussion, March 3, 2025, 11:50 a.m. ET.<\/li>\n<li>Leerink Global Healthcare Conference, Miami, FL. Fireside discussion, March 10, 2025, 9:20 a.m. ET.<\/li>\n<\/ul>\n<p align=\"justify\">Access to a live webcast of the TD Cowen and Leerink events, as well as an archived recording, will be available under the \u201cEvents &amp; Presentations\u201d tab on the Investors &amp; Media section of the Company\u2019s <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=10kBeJCreyH6j5XrrJvWeCIc2dFTP51nw5xHkscqDppwIZFvUFMMP2cxxgyC6bqhawTwfmb_p_P5fvbfhNYHyGuOmBRO-pJN6rE7aetBhWg=\" rel=\"nofollow\" target=\"_blank\"><u>website<\/u>.<\/a><\/p>\n<p align=\"justify\">\n        <strong>About Zentalis Pharmaceuticals<\/strong><br \/>\n        <br \/> Zentalis<sup>\u00ae<\/sup> Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company developing azenosertib (ZN-c3), a potentially first-in-class and best-in-class WEE1 inhibitor for patients with Cyclin E1+ platinum-resistant ovarian cancer (PROC). Azenosertib is being evaluated as a monotherapy and in combination across multiple tumor types in clinical trials and has broad franchise potential. In clinical trials, azenosertib has been well tolerated and has demonstrated anti-tumor activity as a single agent across multiple tumor types. The Company is also leveraging its extensive experience and capabilities to translate its science to advance research on additional areas of opportunity for azenosertib outside PROC. Zentalis has operations in San Diego.<\/p>\n<p align=\"justify\">For more information, please visit <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=atC-kIPEnLuGMfi7ZQ_HTu55ITBOg-JOT5__Ld0axdPHdDTLkiHqz6xE999NjD_sH8LWm2-t8Skc_10YXDNPBxKsJNIfD72TmB9Vjxq7vl4=\" rel=\"nofollow\" target=\"_blank\">www.zentalis.com.<\/a> Follow Zentalis on X\/Twitter at\u00a0<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=lz_rNCT-AXVcMI8V2ydbLfDiecGhQUQnYJZfCXADDRjSdvifqdESrjo_XdN2hrE1Wzat1lRuTQFOq0hQdiNNFw==\" rel=\"nofollow\" target=\"_blank\">@ZentalisP<\/a> and on LinkedIn at <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=Xf4MbC0O1OK4qWCHHKqwACLPB6n-Uj6-P8RSDSy9e-btH2PIifbFVkd69FK1nAKcY-TItSTWgotmFVbGyvQiIRvoLUtCJk_HXekwe05z3ZlUuhCFVpFXOkVQ5IJrLRHEggQOmuaY6CMVA2HGAWwx47UBcC0DxLl72m5lU50d_EWjMErWaeP7SMBxllk7IJin\" rel=\"nofollow\" target=\"_blank\">www.linkedin.com\/company\/zentalis-pharmaceuticals.<\/a><\/p>\n<p align=\"start\">\n        <strong>Contact:<\/strong>\n      <\/p>\n<p align=\"start\">Haibo Wang &#8211; Chief Business Officer <br \/>Ron Moldaver &#8211; Investor Relations <br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=nTXGZEBvMzPob6xJYW0hlfmUD9JtO9JAIo-IE8FBdrRS0Y0Q7ggmZ7KNIaNRW3KG13J6GgO5sSDGbCu-0J-1ig==\" rel=\"nofollow\" target=\"_blank\"><u>ir@zentalis.com<\/u><\/a><\/p>\n<p>      <img decoding=\"async\" alt=\"\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTM4MzU0NCM2Nzc1NDIyIzIxOTQ3NDM=\" \/><br \/>\n      <br \/>\n      <img decoding=\"async\" alt=\"\" src=\"https:\/\/ml.globenewswire.com\/media\/ZDYyNTUxNDgtOTc2NC00YTAxLTkxMzMtN2Y2MDRmMTM1YjJkLTEyMDYyOTY=\/tiny\/ZENTALIS-PHARMACEUTICALS.png\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>SAN DIEGO, Feb. 24, 2025 (GLOBE NEWSWIRE) &#8212; Zentalis\u00ae Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical-stage biopharmaceutical company developing a potentially first-in-class and best-in-class WEE1 inhibitor for patients with ovarian cancer and other tumor types, today announced that members of the management team will participate in the following upcoming investor conferences: TD Cowen 45th Annual Health Care Conference, Boston, MA. Fireside discussion, March 3, 2025, 11:50 a.m. ET. Leerink Global Healthcare Conference, Miami, FL. Fireside discussion, March 10, 2025, 9:20 a.m. ET. Access to a live webcast of the TD Cowen and Leerink events, as well as an archived recording, will be available under the \u201cEvents &amp; Presentations\u201d tab on the Investors &amp; Media section of the Company\u2019s website. About Zentalis &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/zentalis-pharmaceuticals-to-participate-in-upcoming-investor-conferences\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Zentalis Pharmaceuticals to Participate in Upcoming Investor Conferences&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-817020","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.5 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Zentalis Pharmaceuticals to Participate in Upcoming Investor Conferences - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/zentalis-pharmaceuticals-to-participate-in-upcoming-investor-conferences\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Zentalis Pharmaceuticals to Participate in Upcoming Investor Conferences - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"SAN DIEGO, Feb. 24, 2025 (GLOBE NEWSWIRE) &#8212; Zentalis\u00ae Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical-stage biopharmaceutical company developing a potentially first-in-class and best-in-class WEE1 inhibitor for patients with ovarian cancer and other tumor types, today announced that members of the management team will participate in the following upcoming investor conferences: TD Cowen 45th Annual Health Care Conference, Boston, MA. Fireside discussion, March 3, 2025, 11:50 a.m. ET. Leerink Global Healthcare Conference, Miami, FL. Fireside discussion, March 10, 2025, 9:20 a.m. ET. Access to a live webcast of the TD Cowen and Leerink events, as well as an archived recording, will be available under the \u201cEvents &amp; Presentations\u201d tab on the Investors &amp; Media section of the Company\u2019s website. About Zentalis &hellip; Continue reading &quot;Zentalis Pharmaceuticals to Participate in Upcoming Investor Conferences&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/zentalis-pharmaceuticals-to-participate-in-upcoming-investor-conferences\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2025-02-24T21:25:42+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTM4MzU0NCM2Nzc1NDIyIzIxOTQ3NDM=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/zentalis-pharmaceuticals-to-participate-in-upcoming-investor-conferences\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/zentalis-pharmaceuticals-to-participate-in-upcoming-investor-conferences\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Zentalis Pharmaceuticals to Participate in Upcoming Investor Conferences\",\"datePublished\":\"2025-02-24T21:25:42+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/zentalis-pharmaceuticals-to-participate-in-upcoming-investor-conferences\\\/\"},\"wordCount\":265,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/zentalis-pharmaceuticals-to-participate-in-upcoming-investor-conferences\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTM4MzU0NCM2Nzc1NDIyIzIxOTQ3NDM=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/zentalis-pharmaceuticals-to-participate-in-upcoming-investor-conferences\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/zentalis-pharmaceuticals-to-participate-in-upcoming-investor-conferences\\\/\",\"name\":\"Zentalis Pharmaceuticals to Participate in Upcoming Investor Conferences - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/zentalis-pharmaceuticals-to-participate-in-upcoming-investor-conferences\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/zentalis-pharmaceuticals-to-participate-in-upcoming-investor-conferences\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTM4MzU0NCM2Nzc1NDIyIzIxOTQ3NDM=\",\"datePublished\":\"2025-02-24T21:25:42+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/zentalis-pharmaceuticals-to-participate-in-upcoming-investor-conferences\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/zentalis-pharmaceuticals-to-participate-in-upcoming-investor-conferences\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/zentalis-pharmaceuticals-to-participate-in-upcoming-investor-conferences\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTM4MzU0NCM2Nzc1NDIyIzIxOTQ3NDM=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTM4MzU0NCM2Nzc1NDIyIzIxOTQ3NDM=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/zentalis-pharmaceuticals-to-participate-in-upcoming-investor-conferences\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Zentalis Pharmaceuticals to Participate in Upcoming Investor Conferences\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Zentalis Pharmaceuticals to Participate in Upcoming Investor Conferences - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/zentalis-pharmaceuticals-to-participate-in-upcoming-investor-conferences\/","og_locale":"en_US","og_type":"article","og_title":"Zentalis Pharmaceuticals to Participate in Upcoming Investor Conferences - Market Newsdesk","og_description":"SAN DIEGO, Feb. 24, 2025 (GLOBE NEWSWIRE) &#8212; Zentalis\u00ae Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical-stage biopharmaceutical company developing a potentially first-in-class and best-in-class WEE1 inhibitor for patients with ovarian cancer and other tumor types, today announced that members of the management team will participate in the following upcoming investor conferences: TD Cowen 45th Annual Health Care Conference, Boston, MA. Fireside discussion, March 3, 2025, 11:50 a.m. ET. Leerink Global Healthcare Conference, Miami, FL. Fireside discussion, March 10, 2025, 9:20 a.m. ET. Access to a live webcast of the TD Cowen and Leerink events, as well as an archived recording, will be available under the \u201cEvents &amp; Presentations\u201d tab on the Investors &amp; Media section of the Company\u2019s website. About Zentalis &hellip; Continue reading \"Zentalis Pharmaceuticals to Participate in Upcoming Investor Conferences\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/zentalis-pharmaceuticals-to-participate-in-upcoming-investor-conferences\/","og_site_name":"Market Newsdesk","article_published_time":"2025-02-24T21:25:42+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTM4MzU0NCM2Nzc1NDIyIzIxOTQ3NDM=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/zentalis-pharmaceuticals-to-participate-in-upcoming-investor-conferences\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/zentalis-pharmaceuticals-to-participate-in-upcoming-investor-conferences\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Zentalis Pharmaceuticals to Participate in Upcoming Investor Conferences","datePublished":"2025-02-24T21:25:42+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/zentalis-pharmaceuticals-to-participate-in-upcoming-investor-conferences\/"},"wordCount":265,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/zentalis-pharmaceuticals-to-participate-in-upcoming-investor-conferences\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTM4MzU0NCM2Nzc1NDIyIzIxOTQ3NDM=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/zentalis-pharmaceuticals-to-participate-in-upcoming-investor-conferences\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/zentalis-pharmaceuticals-to-participate-in-upcoming-investor-conferences\/","name":"Zentalis Pharmaceuticals to Participate in Upcoming Investor Conferences - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/zentalis-pharmaceuticals-to-participate-in-upcoming-investor-conferences\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/zentalis-pharmaceuticals-to-participate-in-upcoming-investor-conferences\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTM4MzU0NCM2Nzc1NDIyIzIxOTQ3NDM=","datePublished":"2025-02-24T21:25:42+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/zentalis-pharmaceuticals-to-participate-in-upcoming-investor-conferences\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/zentalis-pharmaceuticals-to-participate-in-upcoming-investor-conferences\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/zentalis-pharmaceuticals-to-participate-in-upcoming-investor-conferences\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTM4MzU0NCM2Nzc1NDIyIzIxOTQ3NDM=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTM4MzU0NCM2Nzc1NDIyIzIxOTQ3NDM="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/zentalis-pharmaceuticals-to-participate-in-upcoming-investor-conferences\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Zentalis Pharmaceuticals to Participate in Upcoming Investor Conferences"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/817020","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=817020"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/817020\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=817020"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=817020"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=817020"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}